We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
- Authors
Minichillo, Santino; Gallelli, Ilaria; Barbieri, Elena; Cubelli, Marta; Rubino, Daniela; Quercia, Sara; Dall'Olio, Massimo; Rapezzi, Claudio; Zamagni, Claudio
- Abstract
<bold>Background: </bold>Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with trastuzumab alone.<bold>Case Presentation: </bold>We report the case of a 49 year-old woman affected by metastatic breast cancer who developed trastuzumab-related cardiogenic shock due to pump failure (with LVEF of about 15%) after three months of treatment. After a long hospitalization in the cardiac intensive care unit and a proper treatment, LVEF increased to 50% and, due to a severe progression of disease, trastuzumab was resumed and continued for more than one year.<bold>Conclusion: </bold>This is a case of particularly severe cardiotoxicity related to trastuzumab treatment, which was recovered with pharmacological treatment and the temporary discontinuation of the treatment. Trastuzumab was safely resumed after clinical and echocardiographic parameters improvement.
- Publication
BMC Cancer, 2017, Vol 17, p722
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-017-3712-8